| Name | ZN-c3 |
|---|---|
| Synonyms |
(R)-2-Allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
3H-Pyrazolo[3,4-d]pyrimidin-3-one, 1-[(7R)-7-ethyl-6,7-dihydro-7-hydroxy-5H-cyclopenta[b]pyridin-2-yl]-1,2-dihydro-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)- (ACI) azenosertib Azenosertib (Zn-C3) ZN-c3, 10 mM in DMSO 3H-Pyrazolo[3,4-d]pyrimidin-3-one, 1-[(7R)-7-ethyl-6,7-dihydro-7-hydroxy-5H-cyclopenta[b]pyridin-2-yl]-1,2-dihydro-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl) 1-[(7R)-7-ethyl-7-hydroxy-5,6-dihydrocyclopenta[b]pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one Zn-C3 ZNc3,ZN c3 |
| Description | ZN-c3 is an orally active, highly potent and selective Wee1 inhibitor (IC50=3.9 nM). ZN-c3 can be used for the research of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
IC50: 3.9 nM (Wee1)[1] |
| In Vitro | ZN-c3 IC50 is 103 nM in H23c cells[1]. |
| In Vivo | ZN-c3 (80 mg/kg; p.o.; 28 days) can effectively shrank tumors at 80 mg/kg as a single agent[1]. ZN-c3 shows excellent exposures and bioavailability in the dog PK study[1]. |
| References |
| Molecular Formula | C29H34N8O2 |
|---|---|
| Molecular Weight | 526.63 |
| Storage condition | -20°C |